(1)
🧬 The Catalyst: NV-387 and the Measles Crisis (1)(8)(9)
The company’s latest announcement confirmed that its lead broad-spectrum antiviral, NV-387, has shown strong activity without toxicity
against the Measles virus in a humanized animal model.
The company added that the medication can now be made available for emergency-use applications in Measles cases — exactly as the United States faces its worst outbreak in more than three decades.
🦠 The CDC has confirmed over 1,600 cases this year, breaking a 30-year record.
South Carolina just reported 15 active
cases with more than 100 students quarantined, while new clusters in Ohio follow earlier flare-ups in Texas.
“We have already developed an effective dr.ug to respond to the Measles virus outbreaks spreading all across the country,” said company president Dr. Anil R. Diwan.
That statement changes the conversation.
With NV-387
already through Phase I human trials and no reported adverse events, NNVC can now support Physician-Initiated INDs — the regulatory pathway that lets doctors request emergency use for individual patients.
In short: the door is open for this compound to enter the real world.
⚙️ What Makes NV-387 Different (7)(8)(9)
NV-387 isn’t a
vaccine or an antibody.
It’s a nanotech-based antiviral designed to trick viruses into binding to engineered polymers that mimic human cell receptors. Once the virus attaches, the polymer destroys it — attacking both extracellular and intracellular infection pathways.
That dual action could make NV-387 effective across a wide range of pathogens. The company says its design targets binding sites shared
by about 90% of human viruses, giving it genuine broad-spectrum potential.
In animal studies, NV-387 has shown strong results against RSV, Influenza, COVID-19, and Smallpox/Mpox.
In a Measles model, it increased survival by 130% compared to untreated controls with no observed toxicity. By contrast, Ribavirin — the only unapproved fallback sometimes used off-label for Measles — is known to
be highly toxic.
NV-387 is already manufactured under GMP standards in the U.S., and the company notes it can be produced as oral gummies that dissolve slowly in the mouth — a useful detail for symptomatic patients.
🧩 Broader Pipeline Context (1)(4)(7)
NanoViricides is positioning NV-387 as
a platform medication, not a single-virus solution. The same molecule is being advanced for multiple respiratory and epidemic threats including Bird Flu (H5N1), RSV, Influenza, COVID-19, and Mpox/Smallpox.
Earlier this year, regulators in the Democratic Republic of Congo cleared NNVC to file a Phase II
clinical-trial application for NV-387 in Mpox disease, a virus with a fatality rate several times higher than COVID’s.
A second candidate, NV-HHV-1, is in preparation for Phase I studies targeting all Herpes-family viruses, including HSV-1 cold sores, HSV-2 genital ulcers, and shingles.
Each of these programs draws from the same nanoviricide framework — one chemistry, many targets — a model that could
eventually scale into multiple therapeutic categories.
